Emerging epidemic of transmitted HIV drug resistance in low- and middle-income countries, with highest burden seen in MSM
Longer time to virological failure and less drug resistance seen in people taking Atripla than in people taking separate drugs
Dolutegravir demonstrates good efficacy despite resistance